10-1-2013

Characterization and optimization of the glucan particle-based vaccine platform

Haibin Huang  
*University of Massachusetts Medical School, Haibin.Huang@umassmed.edu*

Gary R. Ostroff  
*University of Massachusetts Medical School, Gary.Ostroff@umassmed.edu*

Chrono K. Lee  
*University of Massachusetts Medical School, Chrono.Lee@umassmed.edu*

*See next page for additional authors*

Follow this and additional works at:  [http://escholarship.umassmed.edu/faculty_pubs](http://escholarship.umassmed.edu/faculty_pubs)  

Part of the [Immunity Commons](http://escholarship.umassmed.edu/immunity_commons), [Immunoprophylaxis and Therapy Commons](http://escholarship.umassmed.edu/immunoprophylaxis_and_therapy_commons), [Medical Immunology Commons](http://escholarship.umassmed.edu/medical_immunology_commons), and the [Medicinal-Pharmaceutical Chemistry Commons](http://escholarship.umassmed.edu/medicinal_pharmaceutical_chemistry_commons)

Repository Citation  
Huang, Haibin; Ostroff, Gary R.; Lee, Chrono K.; Specht, Charles A.; and Levitz, Stuart M., "Characterization and optimization of the glucan particle-based vaccine platform" (2013). *University of Massachusetts Medical School Faculty Publications*. Paper 762.  
[http://escholarship.umassmed.edu/faculty_pubs/762](http://escholarship.umassmed.edu/faculty_pubs/762)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of Massachusetts Medical School Faculty Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Characterization and optimization of the glucan particle-based vaccine platform

Authors
Haibin Huang, Gary R. Ostroff, Chrono K. Lee, Charles A. Specht, and Stuart M. Levitz

Comments
Copyright © 2013, American Society for Microbiology. All Rights Reserved. Publisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.

Rights and Permissions
Glucan particles (GPs) are hollow porous *Saccharomyces cerevisiae* cell walls that are treated so that they are composed primarily of β-1,3-d-glucans. Our previous studies showed that GPs can serve as an effective vaccine platform. Here, we characterize CD4⁺ T-cell and antibody responses in immunized mice as a function of antigen (ovalbumin) encapsulation, antigen dose, particle numbers, time, immunization schedule, and trapping methods. Although we found that GPs served as an effective adjuvant when admixed with free antigens for IgG1 antibody production, stronger CD4⁺ T-cell and IgG2c antibody responses were stimulated when antigens were encapsulated inside GPs, suggesting that the GP platform acts as both an adjuvant and a delivery system. Vigorous T-cell and antibody responses were stimulated even at submicrogram antigen doses, as long as the number of GPs was kept at 5 × 10⁷ particles per immunization. One prime and one boost were sufficient to elicit robust immune responses. In addition, strong antigen-specific antibody and T-cell responses prevailed up to 20 months following the last immunization, including those of gamma interferon (IFN-γ), interleukin 17A (IL-17A), and dual IFN-γ/IL-17A-secreting CD4⁺ T cells. Finally, robust immune responses were observed using generally recognized as safe (GRAS) materials (alginate and calcium, with or without chitosan) to trap antigens within GPs. Thus, these studies demonstrate that antigens encapsulated into GPs make an effective vaccine platform that combines adjuvanticity and antigen delivery to elicit strong durable immune responses at relatively low antigen doses using translationally relevant formulations.

The development of vaccines is one of the greatest achievements in the history of medicine. Vaccines can be classified as live attenuated and inactivated. While live vaccines typically generate longer lasting immunity, they tend to have a poorer safety profile and are contraindicated in immunocompromised persons. Among the inactivated vaccines, subunit vaccines have the theoretical advantage of being safer, but the antigens used in them generally have little to no intrinsic antigenicity and therefore require administration with adjuvants (1).

The most commonly used adjuvant in clinical use, aluminum salts (alum), generally elicits strong antibody responses to coadministered antigens. However, there is a critical need for adjuvants that stimulate protective T-cell responses against those diseases for which antibodies alone are not protective. To this end, we have developed a glucan particle (GP)-based vaccine platform (2). GPs are derived from *Saccharomyces cerevisiae* and predominantly consist of β-1,3-d-glucans (3). β-1,3-d-Glucans are fungal cell wall pathogen-associated molecular patterns (PAMPs) (4, 5) that are recognized by host phagocytic β-1,3-d-glucan receptors, including Dectin-1 (6), CR3 (7), and scavenger receptors (8-10). β-1,3-d-Glucans also activate the alternative pathway of complement, with deposition of C3 fragments that are recognized by complement receptors (11).

We have shown that mice immunized three times with GPs containing ovalbumin complexed with yeast RNA develop robust antigen-specific antibody and Th1- and Th17-biased CD4⁺ T-cell responses (2). The goals of the present study were to address unanswered issues that are relevant to the development of GP-based vaccines for eventual use in humans. The importance of GPs as an adjuvant independent of its antigen delivery properties was determined by comparing immune outcomes when antigens were simply mixed with GPs versus being encapsulated inside GPs. Vaccines that are dose sparing and elicit rapid immune responses may be lifesaving in urgent situations, such as during influenza pandemics or in response to bioterrorism threats. Therefore, we examined the antibody and T-cell responses that occur when reducing the (i) amount of antigen loaded into GPs, (ii) number of GPs per immunization, and (iii) number of boosters. Long-term immunity is desirable for most vaccines but has been difficult to achieve with inactivated vaccines. Here, we studied the durability of immune responses up to 20 months postimmunization. Finally, we addressed issues of safety in and translation to human use by examining the immunogenicity of GPs formulated with antigen-entrapping materials (alginate, calcium, and chitosan) that are generally recognized as safe (GRAS) by the U.S. Food and Drug Administration.

MATERIALS AND METHODS

Chemicals and cell culture media. Chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. RPMI 1640 medium was purchased from Invitrogen Life Technologies (Carlsbad, CA). R10 medium, made of RPMI 1640 containing 10% fetal bovine serum (FBS) (Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine (Invitrogen), and 55 μM 2-mercaptoethanol (2-ME) (Invitrogen) was also used. Chicken ovalbumin (OVA) containing ≤1 endotoxin unit per mg was purchased from Worthington Biochemical Corporation (Lakewood, NJ). Mouse serum albu-
mice were left unstimulated or cultured with OVA (final concentration, and splenocytes (red blood cells were removed) from immunized or naive mice were left unstimulated or cultured with OVA (final concentration, 100 μg/ml) for 24 to 28 h. Brefeldin A was added for the last 5 h of incubation. The cells were collected and stained with LIVE/DEAD blue fixable dead cell stain kit (Invitrogen), according to the manufacturer’s protocol. Then the cells were blocked with Fc-blocking antibodies (BD Biosciences) and stained for surface antigens (CD3 [fluorescein isothiocyanate (FITC)], CD4 [V500], and CD8 [V450]). After fixation and permeabilization using the Cytofix/Cytoperm fixation/permeabilization kit (BD Biosciences), the cells were stained with labeled antibodies (BD Biosciences) against mouse IFN-γ (Alexa 700) and interleukin 17A (IL-17A) (phycoerythrin [PE]). Single-color controls for LIVE/DEAD blue were prepared using amine reactive compensation (ARC) beads (Invitrogen) according to the manufacturer’s protocol. Single-color controls for CD3, CD4, CD8, IFN-γ, and IL-17A were prepared using CompBeads (BD Biosciences) according to the manufacturer’s protocol. Fluorescence-activated cell sorters (FACS) data were collected using an LSR II flow cytometer (BD) and analyzed using FlowJo software (Tree Star, Ashland, OR). Briefly, the dead cells were excluded using the LIVE/DEAD blue signal, the CD4+ CD8+ population was selected from the CD3+ population, and finally the expression of IFN-γ and IL-17A on the live CD3+ CD4+ CD8− gated population was examined.

**Statistics.** Data were analyzed and the figures prepared using GraphPad Prism software. For lymphoproliferation and ELISpot results, we performed a one-way analysis of variance (ANOVA) with the Tukey multiple comparison for comparisons of three or more groups; comparisons of two groups were performed by two-tailed unpaired Student’s t test with a Bonferroni correction applied for multiple comparisons. For antibody titer data, nonparametric analyses were performed. Specifically, Kruskal-Wallis analysis was performed for comparisons of three or more groups and Mann-Whitney analysis for comparisons of two groups. Significance was defined as a P value of <0.05.

**RESULTS**

Effect of antigen encapsulation on stimulation of immune responses. β-Glucans have been exploited in experimental vaccines for both their adjuvant and delivery properties (14, 15). To evaluate the relative contributions of these properties to the immunogenicity of GP-based vaccines, we compared the antigen–specific responses in mice immunized with OVA complexed inside GPs (i.e., GPs acting as both a delivery system and adjuvant) versus OVA and GPs that were admixed (i.e., GPs acting only as an adjuvant). Thus, mice received either a mixture of GPs (GP-MSA/tR) and free OVA (GP + OVA) or OVA encapsulated inside GPs (GP-OVA/tR). Only GP-OVA/tR stimulated CD4+ T-cell responses, as measured by the lymphoproliferation assays (Fig. 1A) and ELISpot (Fig. 1B). As in our previous studies (2), the Th1 and Th17 responses greatly exceeded the Th2 response, as judged by the number of IFN-γ− and IL-17A− versus IL-4+ positive “spots.” Both formulations stimulated comparable IgG1 antibody titers (Fig. 1C), but GP-OVA/tR stimulated significantly higher levels of IgG2c antibodies (Fig. 1D). These results suggest that although GPs have some adjuvanticity when mixed with antigens, GPs with encapsulated antigens stimulate much stronger overall immune responses. This was particularly pronounced for CD4 cellular immunity.

**GP vaccines efficiently stimulate robust immune responses over a wide range of encapsulated antigen concentrations.** The antigen-sparing properties of vaccines are important when antigens are in short supply, such as might occur during an acute outbreak. We previously used a relatively high dose of antigen (50 μg) in order to establish the potential utility of GP-based vaccines (2). To determine the efficiency of the platform at lower antigen doses, we loaded various amounts of OVA (0.5, 5, and 50 μg) into 5 X 10^7 GPs and immunized the animals with these GP-OVA/tR formulations. Similar CD4 T-cell responses, as
measured by CD4⁺ T-cell lymphoproliferation (Fig. 2A) and ELISpot (Fig. 2B), as well as IgG1 (Fig. 2C) antibody responses were stimulated. The lowest dose (0.5 μg) stimulated significantly lower IgG2c antibody responses than did the highest dose (50 μg) (Fig. 2D).

These data establish that the GP vaccine platform is immunogenic even at submicrogram antigen doses.

**GP numbers are important for mounting strong immune responses.** In the above-mentioned experiment, we varied the amount
of antigens but kept the numbers of GPs per immunization constant. In the next set of experiments, we sought to determine the critical number of GPs needed to obtain vigorous immune responses. To do this, we immunized sets of mice with the same GP formulations (50 μg OVA per 5 × 10^7 GPs) but varied the number of GPs the mice received. We found that only the group receiving the largest amount of particles (5 × 10^7 GP-OVA/tR per dose, containing 50 μg OVA) stimulated robust immune responses (Fig. 3A to D). Groups receiving fewer particles (5 × 10^5 to 5 × 10^6, delivering 0.5 to 5 μg OVA) had little to no responses. By comparing the groups immunized with the same amount of OVA but different numbers of GPs (Fig. 2 and 3), it is apparent that a critical number of GPs is needed to elicit robust immune responses.

One boost is sufficient to mount robust immune responses. For the aforementioned immunization schemes, we gave two boosts following the priming dose. Given that reducing the number of boosts would have obvious benefits for vaccination programs, we compared the antigen-specific responses in mice immunized once (prime only), twice (prime plus boost), or three times (prime plus two boosts). We found that CD4^+ T-cell proliferative responses and OVA-specific IgG1 and IgG2c antibodies did not significantly differ when comparing one boost with two boosts (Fig. 4A to C). However, immunization with only a prime did not elicit strong immune responses.

GP vaccines stimulate long-term durable responses. Ideal vaccines stimulate long-lasting immune responses. Therefore, we next evaluated the durability of the responses following GP-OVA/tR immunization (prime and two boosts). In the first set of experiments, OVA-specific CD4^+ T-cell lymphoproliferation (Fig. 5A), ELISpot (Fig. 5B), IgG1 (Fig. 5C), and IgG2c (Fig. 5D) responses were found to be strong seven to eight months following the last immunization. We then examined intracellular IFN-γ and IL-17A

**FIG 3** Effect of GP number and antigen concentration on immune responses. Mice were immunized three times at 2-week intervals with the indicated number of GP-OVA/tR (containing 50 μg OVA per 5 × 10^7 particles; 5 μg OVA per 5 × 10^6 particles; 0.5 μg per 5 × 10^5 particles). Two or 4 weeks after the last immunization, CD4^+ T-cell lymphoproliferation (A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D) were performed. Data shown are combined results from two independent experiments with 4 or 5 mice per group for each experiment. Some of the data for the 5 × 10^7 GP group are also used in Fig. 1 (part of the GP-OVA/tR group) and Fig. 2 (50 μg OVA group). **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

**FIG 4** Effect of number of GP immunizations on immune responses. Mice were immunized once (prime only), twice (prime and one boost), or three times (one prime and two boosts) with 5 × 10^7 GP-OVA/tR (containing 50 μg OVA per 5 × 10^7 particles) per dose. Immunizations were at 2-week intervals for those mice that received boosts. Three weeks after the last immunization, CD4^+ T-cell lymphoproliferation (A), IgG1 (B), and IgG2c (C) were performed. Data are combined results from two independently performed experiments, with four mice per group for each experiment. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
staining in CD4+ T cells 18 to 20 months following the last immunization. We found that ex vivo OVA stimulation resulted in increases in IFN-γ-, IL-17A-, and dual IFN-γ/IL-17A-secreting CD4+ T cells from immunized, but not naive, mice (Fig. 5E to H). In addition, the OVA-specific reciprocal antibody titers from the two mice were 163,840 and 20,480 for IgG1 and 640 and 640 for IgG2c. These results suggest that GP vaccines might stimulate long-term durable immune responses.

GP formulations using GRAS materials. In our previous studies, yeast RNA was used to trap OVA in GPs because of its effectiveness in complexing serum albumins inside GPs. To increase the translational relevance of the GP platform, we tested several GRAS materials (alginate and calcium, with or without chitosan) as antigen-trapping agents. GP formulations containing either alginate and calcium or alginate, calcium, and chitosan were comparable to RNA-based formulations in their capacity to induce antigen-specific T-cell and antibody responses in mice (Fig. 6A to D).

DISCUSSION

Our previous studies established that antigens encapsulated in GPs stimulate potent CD4+ T- and B-cell responses when given subcutaneously to mice (2, 13). Here, we studied the properties of the GP-based vaccine platform, particularly focusing on aspects relevant to human development, including antigen sparing, dose optimization, memory responses, and formulation composition. We found that the GP platform stimulates strong and durable immune responses to encapsulated antigens, even at submicrogram doses. While a single boost following the prime was sufficient to mount strong responses, optimal T-cell responses required a critical number of GPs per immunization. Finally, GP formulations that incorporated GRAS materials as trapping components retained immunogenicity. These findings broaden our understanding of the GP platform and should enhance its prospects for future clinical development.

GPs target antigens to APCs bearing β-glucan and complement receptors (2, 13). In addition to their targeting properties, β-glucans have intrinsic adjuvant activity (14). Moreover, C5a, which is generated as a result of complement activation by GPs (11), has been used as an adjuvant (16). Therefore, it was of interest to distinguish the antigen-targeting and intrinsic adjuvant properties of GPs. Our data demonstrating that GP formulations containing encapsulated OVA elicited superior immune responses to those of immunizations consisting of a simple mix of GPs and OVA suggest that the antigen-targeting properties of the GP platform are essential for optimal immunogenicity. However, the finding that a mix of GPs and antigen still generated some responses attests to the intrinsic adjuvant properties of GPs. Interestingly though, mixing GPs and OVA generated significant antibody titers but not CD4+ T-cell responses. Consistent with our data, it has been reported that the host sees more “danger” when antigens are codelivered with PAMPs into the same phagosomal compartment (17). T-cell activation is more efficient when clusters of peptide-major histocompatibility complex (MHC) molecules are displayed on the surfaces of APCs (18). All the antigens delivered to an APC by a single antigen-laden GP should traffic to a distinct phagolysosomal compartment. An antigen load of 0.5 μg of OVA in 5 × 10^7 GPs delivers >100,000 OVA molecules per GP. We speculate that the capability of the GP platform to induce potent
cellular immune responses even at submicrogram antigen doses is due, at least in part, to preferential clustering when peptides are derived from same compartment.

Despite the ability of GPs to target antigen to APCs, immune responses declined when mice received $5 \times 10^7 \text{ GPs per immunization}$. All the major phagocytic populations, including neutrophils, macrophages, and DCs express Dectin-1 and complement receptors and are able to phagocytize GPs. Our preliminary data (H. Huang, G. R. Ostroff, and S. M. Levitz, unpublished data) demonstrate that only a minority of GPs are phagocytosed by DCs at the subcutaneous injection site. As DCs are thought to be the primary cell type that initiates adaptive immune responses, modifying the GP platform to selectively target DCs might result in vaccines that require fewer GPs per dose. While clinical trials are needed to determine the optimal number of GPs in the context of human vaccination, it should be noted that the mass of $5 \times 10^7 \text{ GPs is only } 100 \mu g$.

Ideal vaccines provide protective immunity after a minimum number of immunizations. Reducing the number of immunizations with GP-OVA from three doses to two did not significantly compromise antigen-specific antibody and CD4$^+$ T-cell responses. Although T-cell responses were not detected after a single immunization with GP-OVA, modest antibody responses were observed. While such responses might be useful for protection against diseases that do not require high titers of antibody, future efforts will be directed to develop formulations that elicit more vigorous responses after only a single dose.

It is desirable that vaccination confers long-term protective immunity. We found that following immunization with GPs, antigen-specific responses prevailed for essentially the life span of the mouse. Moreover, even 18 to 20 months following the last immunization, approximately 10% and 2% of the CD4$^+$ T-cell population stained positive for intracellular IFN-$\gamma$ and IL-17A, respectively, following ex vivo stimulation with OVA. These data suggest that long-term Th1 and Th17 memory responses are induced using the GP platform. Although there is controversy regarding the longevity of Th17 cells, our results are consistent with a recent study showing long-lasting Th1 and Th17 memory cells following subunit vaccination with antigens administered with the cationic liposome adjuvant CAF01 (19). Interestingly, in both our study and the aforementioned study, a small but distinctive population of IFN-$\gamma$/IL-17A double-positive antigen-specific CD4$^+$ T cells was detected. The development, plasticity, and functionality of these CD4$^+$ T-cell lineages after immunization remain to be defined.

Regulatory agencies have rigorous safety requirements for new vaccines, including a requirement to test all component parts (1). Thus, translation from preclinical testing to clinical trials and eventual human approval is facilitated by the use of GRAS materials. As yeast RNA is not considered a GRAS material by the FDA, we studied whether combinations of alginate and calcium, with and without chitosan, three materials that are GRAS, could be substituted for RNA to trap OVA inside GPs. We found that the combination of alginate plus calcium was slightly inferior to the standard yeast RNA formulation at stimulating some T-cell responses. However, the addition of chitosan to alginate and calcium resulted in antibody and T-cell responses similar to those stimulated by RNA-based formulations. While chitosan has been shown to activate the inflammasome (20), additional studies will be needed to determine whether inflammasome activation contributes to the enhanced immunogenicity of chitosan-containing GPs.

Finally, our studies utilized responses to OVA to assess variables that affect the immunogenicity of the GP platform. It is

FIG 6 GP formulations containing GRAS materials. Mice (four per group) were immunized three times at 2-week intervals with $5 \times 10^7 \text{ particles containing } 5 \mu g \text{ OVA per dose}$. Three methods of encapsulations were compared: yeast tRNA (tR) (GP-OVA/tR), alginate and calcium (AC) (GP-OVA/AC), and alginate, calcium, and chitosan (ACC) (GP-OVA/ACC). Mice were euthanized 4 weeks after the 3rd immunization, following which CD4$^+$ T-cell lymphoproliferation (A), ELISpot (B), IgG1 ELISA (C), and IgG2c ELISA (D) were performed. Results are from one experiment. Data for the tR group are also used in Fig. 2 (part of the 5 $\mu g \text{ OVA group}).$ Comparable results were obtained from a similarly designed experiment (mice were immunized three times at 2-week intervals with $5 \times 10^7 \text{ respective GP-OVA constructs containing } 3.3 \mu g \text{ OVA per dose}).$, $^*, P < 0.05.$
appreciated that immune responses to model antigens, while informative, cannot be relied upon to predict vaccine-mediated protection. In this regard, in published (21) and unpublished works, we have begun to study GP-based vaccines in models of infection, with encouraging results.

ACKNOWLEDGMENTS

This work was supported in part by Public Health Service grant no. AI025780, AI093302, AI102618, HL112671, and AI094074 from the National Institutes of Health.

REFERENCES